Evidence map›Paper›PMID 38712735›Full record

ArticleInternational journal of immunopathology and pharmacology

Revealing the potential of solute carrier family 31 (copper transporters), member 1: Insights into its role in bladder cancer progression and therapeutic implications.

Yun-Zhi Lin, Wei-Hui Liu, Yu-Peng Wu, Hai Cai, Qing-Shui Zheng, Yong Wei, Ning Xu, Xue-Yi Xue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yun-Zhi LinDepartment of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Wei-Hui LiuDepartment of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Yu-Peng WuDepartment of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Hai CaiDepartment of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Qing-Shui ZhengDepartment of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Yong WeiDepartment of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Ning XuDepartment of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Xue-Yi XueDepartment of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.ORCID 0009-0007-8812-0005

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Copper Transporter 1Urinary Bladder NeoplasmsAgedBiomarkers, TumorDisease ProgressionDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMutationPrognosisPromoter Regions, GeneticUp-RegulationBiomarkers, TumorCopper Transporter 1SLC31A1 protein, humanbiomarkerbladder cancerdiagnosticprognosticSLC31A1

Identifiers

PMID38712735
PMCPMC11080779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.